Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia.

References:
1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027
2. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009

©2023 Amgen Inc. All rights reserved. USA-CBU-81658 8/23

Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.

August 2023 US.UNB.X.23.00071

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Pneumococcal vaccination isn’t restricted to a specific season. Patients can get vaccinated with Prevnar 20 at any time. Clinicians can help their patients better understand the importance of pneumococcal vaccination. Join Joyce Riley as she gets expert insights from Dr. Lance Sloan, Endocrinologist, Nephrologist, and Metabolist in Lufkin, Texas.

Continuing medical education credits are not available for this program.
© 2023 Pfizer Inc. All rights reserved. PP-PRV-USA-0378

The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.

Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza burden, Dr. Jennifer Caudle speaks with Dr. Ravi Jhaveri, Division Head of Pediatric Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago.

Reference:
1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed April 8, 2022.

USA-FCV-24-0051 08/24

The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.

References:

1. US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download

1. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download

©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23

Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online’s evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California.

© 2023 AbbVie. All rights reserved.
JUVÉDERM and its design are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are the property of their respective owners.

PRT162857 06/23

It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis.

Sponsored by Novartis Pharmaceuticals Corporation.

6/23 278623

Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis.

Sponsored by Novartis Pharmaceuticals Corporation.

6/23 278623